La vendita allo scoperto per Bolt Projects Holdings dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Bolt Projects Holdings. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Bolt Projects Holdings (NASDAQ:BSLK) Azioni, Report sulle vendite allo scoperto

Bolt Projects Holdings

Bolt Projects Holdings Inc develops and produces biomaterials products. Its flagship products from its Vegan Silk Technology Platform, b-silk and xl-silk, are a biodegradable and vegan protein polymer and a replacement for silicone elastomers in beauty and personal care.

Wall-street-shutter3

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

BSLK

INHD

Il settore dei materiali potrebbe essere pronto per una ripresa. Ecco tre azioni che potrebbero essere interessanti per gli investitori.

Settore dei materiali in ripresa? 3 azioni da tenere d&#39;occhio

Bolt Projects Holdings, Inc. - Common Stock

Bolt Projects Holdings Inc

CANG

Cango Enters Definitive Agreement With Founders And EWCL For $70M Class B Share Sale

BranchOut Food Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOF#NASDAQ">BOF</a>), a leading food technology company specializing in its patented GentleDry&#x2122; dehydrated snacks and ingredients, announces the execution of a strategic agreement with Kaufman Kapital LLC, resulting in a $1 million cash infusion through the early exercise of existing warrants. The agreement also includes amendments to existing financing terms that strengthen BranchOut's balance sheet, allow for debt repayment and extend key debt maturities.
Under the terms of the agreement, Kaufman Kapital will exercise in full an existing warrant to purchase 1,000,000 shares of BranchOut's common stock, providing the Company with $1,000,000 in cash proceeds no later than June 16, 2025.
In addition, the parties agreed to the following amendments:
<ul>
<li>Extension of the maturity date of the $3.4 million Senior Secured Convertible Promissory Note from December 31, 2025 to December 31, 2026.</li>
<li>Extension of the maturity date on the remaining $875,000 balance of the original $1.2 million Kaufman Senior Secured Promissory Note to December 31, 2025.</li>
<li>Extension of the expiration date of a separate warrant to purchase 500,000 shares to December 31, 2026 &nbsp;</li>
</ul>
"This Agreement reflects the strong confidence Kaufman Kapital has in our long-term growth strategy and operational execution," said Eric Healy, CEO of BranchOut Food. "The warrant exercise provides us with additional capital, while the note extensions improve our financial flexibility and strengthen our balance sheet."
Kaufman Kapital's decision to exercise its warrant ahead of schedule and extend key financing terms reflects continued confidence in BranchOut's trajectory. "We've been closely following BranchOut's progress, and the execution we're seeing across both operations and commercial growth is outstanding," said a spokesperson for Kaufman Kapital. "Our early exercise of the warrant reflects our strong confidence in the team, the business model, and the long-term opportunity. We're bullish on where BranchOut is headed and proud to support their continued momentum."
The $1 million in proceeds from the warrant exercise will be used to pay down outstanding debt obligations as part of BranchOut's broader initiative to eliminate all current liability notes payable by the end of 2025. This strategic use of capital reflects the Company's commitment to strengthening its balance sheet and positioning itself for sustained growth.

BranchOut Food Gets $1M Boost From Kaufman Kapital to Pay Down Debt and Fuel Growth

The new facility expands the Company's three loan agreements to a maximum borrowing capacity from $14.2 million to $23.0 million and extends the maturity date under each respective loan agreement from October 1, 2025 to April 30, 2027.
The additional borrowing capacity provides Solésence with significant financial flexibility to support its strategic objectives, including procurement of key raw materials and supplies at favorable pricing, improvement of lead times associated with packaging and product launches, and empowerment of the company's brand partners to drive product adoption.

Health Care

General

SLSN

Solésence Entered Into Amendments To Its Existing Loan Agreements, Providing Increased Borrowing Capacity To Support The Execution Of Strategic Objectives

Goldman Sachs analyst Jordan Alliger downgrades JB Hunt Transport Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>) from Buy to Neutral and maintains the price target from $164 to $164.

Downgrades

Price Target

Analyst Ratings

JBHT

Goldman Sachs Downgrades JB Hunt Transport Servs to Neutral, Maintains Price Target to $164

<ul>
<li>Strategic combination establishes a market-leading mental health company with a pipeline that includes potentially transformative, rapid-acting psychedelic assets differentiated by their convenient route of administration and short time-in-clinic</li>
<li>Combined company will operate under the name atai Beckley with a joint leadership team and Board that leverage the deep psychedelic, drug development and CNS expertise within both organizations</li>
<li>Topline data from the Phase 2b study of BPL-003 in patients with treatment-resistant depression (TRD) is expected in mid-2025 - the largest controlled trial of mebufotenin (5-MeO-DMT) and the first and only controlled trial to investigate mebufotenin in the U.S.</li>
<li>The all-share transaction is expected to close in the second half of 2025</li>
<li>Concurrent $30.0M private placement by Ferring Ventures S.A. and Adage Capital Partners LP</li>
</ul>

ATAI

atai And Beckley Merger Advances Strategic Vision For Psychedelic Drug Development With Deep CNS Expertise

Goldman Sachs analyst Matt Reustle downgrades Canadian Pacific Kansas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CP#NYSE">CP</a>) from Buy to Neutral and maintains the price target from $91 to $91.

Goldman Sachs Downgrades Canadian Pacific Kansas to Neutral, Maintains Price Target to $91

House Speaker Mike Johnson (R-La.) doubled down on his defense of President Donald Trump's "big, beautiful bill", arguing that those who <a href="https://www.benzinga.com/25/05/45278823/over-5-million-americans-set-to-lose-health-coverage-by-2034-amid-proposed-gop-medicaid-cuts-cbo-analysis">lose Medicaid</a> will do so by personal choice
What Happened: During an appearance <a href="https://www.nbcnews.com/meet-the-press/video/speaker-mike-johnson-denies-trump-bill-threatens-medicaid-coverage-full-interview-240675397944">on</a> NBC's Meet the Press, Johnson was asked about projections that 4.8 million people could lose Medicaid coverage under the new spending bill.
"Those 4.8 million people will not lose their Medicaid unless they choose to do so," he said. According to the plan, childless, able-bodied adults aged 19 to 64 are required to work or volunteer at least 20 hours a week to <a href="https://www.benzinga.com/25/05/45558613/house-advances-trumps-sweeping-one-big-beautiful-bill-after-key-medicaid-tax-and-border-security-changes">maintain eligibility for Medicaid.</a>
"You're telling me that you're going to require the able-bodied — these young men, for example, OK — to only work or volunteer in their community for 20 hours a week, and that's too cumbersome for them? I'm not buying it. The American people are not buying it," Johnson said.
See Also: <a href="https://www.benzinga.com/cannabis/25/06/45714305/elon-musk-says-doge-became-a-whipping-boy-for-everything-real-or-imagined-tesla-ceo-doesnt-agree-with-everything-white-house-does-but-wont-speak-out">Elon Musk Says DOGE Became A &#8216;Whipping Boy&#8217; For Everything Real Or Imagined — Tesla CEO Doesn&#8217;t Agree With Everything White House Does But Won&#8217;t Speak Out: &#8216;Creates A Bone Of Contention&#8217;</a>
On claims that <a href="https://www.benzinga.com/general/health-care/25/05/45344596/house-republicans-push-880-billion-medicaid-cuts-to-renew-trump-tax-breaks-democrat-warns-millions-will-lose-their-health-care">people could lose coverage</a> due to administrative obstacles, he said, "The people who are complaining about losing their coverage are doing so because they can't fulfill the paperwork." He said the policy was based on "common sense."
"When people work, when able-bodied young men work, it's good for them, for their dignity, their purpose, and it's good for the community," he added. "If you can't find a job, then volunteer in your community for 20 hours, and you will meet the requirement."
Defending the bill as a whole, Johnson said: "What Republicans are doing is an important and frankly heroic thing."
He alleged that Medicaid is being misused, saying, "It's intended for young, you know, single, pregnant women and the disabled and the elderly. But what's happening right now is you have a lot of people, for example, young men, able-bodied workers, who are on Medicaid. They're not working when they can."
Why It Matters: According to the Congressional Budget Office, the new provisions are projected to save $625 billion of the targeted $800 billion in savings over the next ten years. The controversial new measures have generated intense debate over the past few weeks.
In April, Trump said he would <a href="https://www.benzinga.com/government/25/04/45064937/donald-trump-threatens-to-veto-any-gop-bill-that-touches-medicaid-or-social-security-if-it-cuts-it-i-would-not-approve">"veto" any bill that includes cuts to Medicaid</a>. However, as the bill evolved, Medicaid cuts became central to its project of reducing federal spending, and <a href="https://www.benzinga.com/general/health-care/25/05/45345409/trumps-big-beautiful-bill-banks-on-huge-medicaid-cuts-as-its-cost-saving-centerpiece-see-who-risks-losing-coverage-under-the-gop-proposal">millions are set to lose coverage</a>.
Johnson previously denied that the bill would cut Medicaid, even as Trump&#8217;s crypto and AI advisor, David Sacks, acknowledged that the <a href="https://www.benzinga.com/25/05/45582778/trumps-big-beautiful-bill-passes-house-what-it-means-for-taxes-student-loans-medicaid-and-more" target="_blank" rel="noreferrer noopener"> bill</a> "cuts <a href="https://www.benzinga.com/general/health-care/25/05/45616625/trump-advisor-david-sacks-admits-new-bill-cuts-880-billion-from-medicaid-as-speaker-mike-johnson-insists-we-have-not-cut-medicaid-and-trump-says-working-class-wont-lose-health-insurance">$880 billion from Medicaid</a> over a decade.&#8221;
On the other hand, Sen.&nbsp;Josh Hawley&nbsp;(R-Mo.) wrote in an op-ed that the Republican party is facing an "identity crisis" and that Medicaid cuts are <a href="https://www.benzinga.com/25/05/45369487/josh-hawley-slams-gop-identity-crisis-over-medicaid-calls-proposed-cuts-morally-wrong-and-politically-suicidal">"morally wrong and politically suicidal."</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/macro-economic-events/25/06/45714800/feds-christopher-waller-signals-caution-on-rate-cut-amid-tariff-driven-inflation-risks">Fed&#8217;s Christopher Waller Signals Caution On Rate Cut Amid Tariff-Driven Inflation Risks</a></li>
</ul>
Photo courtesy: Shutterstock

Politics

Speaker Mike Johnson Says 4.8 Million Won't Lose Medicaid 'Unless They Choose To Do So,' Calls GOP Cuts 'An Important And Frankly Heroic Thing'

Biotech

Financing

Offerings

Xilio Therapeutics Commenced An Underwritten Public Offering Of Pre-funded Warrants To Purchase Shares, Terms Not Disclosed

Taiwan Semiconductor Manufacturing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>)&nbsp;is weighing an <a target="_blank" href="https://www.benzinga.com/topic/tsmc" rel="noreferrer noopener">advanced gigafab in</a> the United Arab Emirates.
The contract chipmaker is exploring a complex of six factories (similar to its Arizona fab), subject to regulatory approval from the Trump administration, given the Gulf nation&#8217;s ties to China and Iran&#8217;s influence in the region.
Taiwan Semiconductor held meetings with&nbsp;Steve Witkoff, the U.S. special representative to the Middle East, and MGX officials, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-05-30/tsmc-is-said-to-evaluate-building-advanced-chip-plant-in-the-uae?sref=TBDibEcD" rel="noreferrer noopener">reported</a> on Friday, citing unnamed sources familiar with the matter.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/asia/25/05/45466444/to-serve-exploding-ai-chip-demand-taiwan-semiconductor-plans-9-advanced-factories" rel="noreferrer noopener">To Serve Exploding AI Chip Demand, Taiwan Semiconductor Plans 9 Advanced Factories</a>
Taiwan Semiconductor accounts for the majority share of advanced chips designed by the likes of&nbsp;Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)&nbsp;and&nbsp;Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) components that serve as the brains of electronic devices and are essential for training artificial-intelligence models.
Taiwan Semiconductor executives visited the UAE in 2024, aspiring for potential geographical diversification amid support from the Biden administration subject to stringent conditions. However, the talks failed to fructify.
After Trump assumed charge, the UAE sought a Taiwan Semiconductor fab and vied for easier access to Nvidia chips for AI data centers.
In March, the UAE announced a <a target="_blank" href="https://www.benzinga.com/25/05/45291509/nvidia-broadcom-amd-surge-as-trump-reshapes-ai-chip-export-rules-to-ease-market-pressure" rel="noreferrer noopener">$1.4 trillion commitment</a> to invest in the U.S.
Wedbush&nbsp;analyst Daniel Ives hailed Saudi Arabia as a <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45424189/nvidia-amazon-tesla-palantir-among-top-beneficiaries-of-1-trillion-saudi-arabia-ai-push-analyst-says" rel="noreferrer noopener">significant area of</a> penetration for the AI revolution after President Trump&#8217;s key trip to the Middle East. Ives noted that the market opportunity in Saudi Arabia could add another $1 trillion to the broader global AI market in the coming years, posing tailwind for Nvidia, Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>),&nbsp;Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>),&nbsp;Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
Price Action: TSM shares&nbsp;are trading lower by 0.94% to $191.50 premarket at&nbsp;last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/media/25/05/45653729/taiwan-semiconductor-and-intel-weigh-benefits-of-asmls-pricey-chipmaking-equipment" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor And Intel Weigh Benefits Of ASML&#8217;s Pricey Chipmaking Equipment</a></li>
</ul>
Image by Jack Hong via Shutterstock

Government

Tech

Media

AMZN

GOOG

GOOGL

MSFT

NVDA

PLTR

TSLA

Taiwan Semiconductor Eyes UAE Gigafab, Seeks Crucial US Green Light

Goldman Sachs analyst Jordan Alliger downgrades CSX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) from Buy to Neutral and maintains the price target from $35 to $35.

Goldman Sachs Downgrades CSX to Neutral, Maintains Price Target to $35

DOLE

Dole Expands Public-Private Partnerships To Broaden Access To Social Services For Costa Rican Farm Workers

Global Net Lease, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNL#NYSE">GNL</a>) ("GNL" or the "Company") today announced the appointment of Robert Kauffman as Non-Executive Chairperson of its Board of Directors (the "Board"), effective immediately. Mr. Kauffman succeeds Sue Perrotty, who resigned from her position as Non-Executive Chairperson but will continue to serve on the Board as an independent director.
Mr. Kauffman, a Co-Founder and former member of the Board of Directors of Fortress Investment Group, joined the GNL Board in March 2024.

Management

Global Net Lease Appoints Robert Kauffman as New Chair After Sue Perrotty Steps Down From Role

USGO

US GoldMining To Join Russell 3000 Index Following Strong Progress At Whistler Gold-Copper Project

Maxar Space Systems, a trusted partner in satellite design and manufacturing, today announced it has been awarded a contract by EchoStar Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATS#NASDAQ">SATS</a>) to manufacture EchoStar XXVI, a high-power geostationary communications satellite based on the Maxar 1300&#x2122; platform.
EchoStar XXVI will deliver robust coverage to DISH TV customers across all 50 U.S. states, including Puerto Rico, and is engineered for dual orbital slot performance, giving EchoStar enhanced operational flexibility to meet evolving customer and network demands.
"EchoStar's selection of the Maxar 1300&#x2122; platform underscores our commitment to delivering high-performance satellites that meet our customers' most demanding requirements," said Chris Johnson, CEO, Maxar Space Systems. "We're proud to continue supporting EchoStar's mission with another spacecraft that offers the proven reliability that Maxar Space Systems is known for in the industry."
The satellite will support EchoStar's mission of providing coverage and continue to ensure high-capacity direct-to-home services across its customer base. EchoStar XXVI is scheduled for delivery in 2028.

SATS

EchoStar Taps Maxar for High-Power Satellite to Serve All 50 States and Puerto Rico

SoftBank Group Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>) and Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) are developing next-generation artificial intelligence memory chips designed to consume half the power of current technology, addressing critical energy challenges in Japan&#8217;s growing data center market.
What Happened: The companies established Saimemory, a joint venture targeting commercialization within the 2020s through a 10 billion yen ($70 million) project, <a href="https://asia.nikkei.com/Business/Tech/Semiconductors/SoftBank-Intel-work-on-AI-memory-chips-that-use-half-as-much-power">reported</a> Nikkei. The initiative focuses on stacked DRAM chips with innovative wiring structures that significantly reduce power consumption compared to existing high-bandwidth memory (HBM).
SoftBank leads the investment with 3 billion yen, while Japan&#8217;s Riken research institute and Shinko Electric Industries are considering participation. The venture leverages Intel&#8217;s technology and patents from the University of Tokyo and other Japanese academic institutions, the report noted.
The project addresses supply chain vulnerabilities as South Korea&#8217;s SK Hynix and Samsung Electronics dominate HBM production. Current HBM technology suffers from low production yields, high costs, and intense energy requirements, creating access challenges for Japanese companies.
&#8220;We want priority for the supply,&#8221; a SoftBank executive said, according to the report, highlighting the strategic importance for the company&#8217;s AI data center plans.
See Also: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45716400/pharma-bro-martin-shkreli-sees-10-trillion-potential-in-palantir-but-cautions-one-bad-quarter-and-its-down-50">&#8216;Pharma Bro&#8217; Martin Shkreli Sees $10 Trillion Potential In Palantir, But Cautions: &#8216;One Bad Quarter And It&#8217;s Down 50%&#8217;</a>
Why It Matters: This development represents Japan&#8217;s attempt to regain semiconductor prominence after losing over 70% DRAM market share in the 1980s to South Korean and Taiwanese competitors. Elpida Memory, Japan&#8217;s last DRAM manufacturer, was acquired by Micron Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) in 2013 following bankruptcy.
SoftBank plans to deploy the <a href="https://www.benzinga.com/media/25/03/44327422/softbank-to-build-676-million-ai-data-center-in-japan-linked-to-openai-partnership">new memory technology in AI training data centers</a>, where processing large datasets requires substantial computing power. The company recently acquired Sharp&#8217;s LCD factory for $676 million to build a 150-megawatt AI data center in Osaka, supporting its OpenAI partnership and broader AI infrastructure strategy.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/06/45716143/trump-administration-set-to-ease-big-bank-rules-in-major-rollback-since-2008-crisis-here-are-the-stocks-and-etfs-investors-could-consider">Trump Administration Set To Ease Big Bank Rules In Major Rollback Since 2008 Crisis: Here Are The Stocks And ETFs Investors Could Consider</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: JHVEPhoto / Shutterstock.com

INTC

SFTBY

SoftBank And Intel Set To Launch $70 Million AI Memory Project In Japan To Slash Power Use

BG-C9074, a B7-H4-targeting ADC (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fmeetings.asco.org%2Fabstracts-presentations%2F249387&amp;esheet=54263182&amp;newsitemid=20250602546858&amp;lan=en-US&amp;anchor=Abstract+%233033&amp;index=2&amp;md5=8296b0d4901d6b49866abc285a0544c0">Abstract #3033</a>)
BeOne presented initial results of the ongoing first-in-human, Phase 1a dose escalation study of BG-C9074 monotherapy in 78 patients with advanced solid tumors, of which more than a quarter were breast cancer patients. BG-C9074, an investigational topoisomerase I inhibitor ADC that targets the B7-H4 protein, which is broadly expressed in breast and gynecologic cancers, is designed with an innovative drug linker to deliver a potent cancer-killing drug directly to the cancer cells.
With limited follow-up among the 56 efficacy-evaluable patients, preliminary clinical responses were observed at multiple dose levels across various tumor types without selection for B7-H4 expression in these heavily pretreated patients. Confirmed overall response rate (ORR) was 16.1% (9/56; 95% CI: 7.6%–28.3%), with 9 confirmed partial responses; unconfirmed ORR was 25.0% (14/56; 14.4%-38.4%) (n=14 partial responses). Confirmed disease control rate (DCR) was 73.2% (59.7%-84.2%) and confirmed clinical benefit rate (CBR) was 17.9% (8.9%-30.4%). Pharmacokinetics (PK) were observed to be approximately dose-proportional across dose levels.
BG-C9074 showed a manageable safety and tolerability profile in patients with B7-H4 advanced solid tumors, including breast cancer. There were 5 dose-limiting toxicities (DLTs) reported among 3 dose levels, all related to treatment: grade 3 fatigue (n=1); grade 3 febrile neutropenia (n=2); and grade 4 platelet count decreased (n=2). The most common treatment-emergent adverse events (TEAEs) were nausea, fatigue, and neutropenia&#x2A;. The most common grade ≥3 TEAEs were neutropenia and thrombocytopenia†. There were no TEAEs leading to treatment discontinuation or death.
These data support the continued development of BG-C9074 in patients with advanced solid tumors. (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06233942&amp;esheet=54263182&amp;newsitemid=20250602546858&amp;lan=en-US&amp;anchor=NCT06233942&amp;index=3&amp;md5=f3706bbfd50f5f88f1f4db378ac2e936">NCT06233942</a>)
BG-68501, a CDK2 inhibitor (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fmeetings.asco.org%2Fabstracts-presentations%2F249388&amp;esheet=54263182&amp;newsitemid=20250602546858&amp;lan=en-US&amp;anchor=Abstract%23+3115&amp;index=4&amp;md5=3d7f13e99b2a5cf6e899ab2ef0a202c8">Abstract# 3115</a>)
Dose-escalation data from the first-in-human, Phase 1a study of a novel CDK2 inhibitor, BG-68501, were presented as a poster today. BG-68501 is designed to address elevated CDK2 activity as well as cyclin E1-driven upregulation, two key resistance mechanisms that often limit the effectiveness of CDK4/6 inhibitors in treating HR+/HER2- breast cancer. CDK inhibitors target checkpoint proteins that control cell division to stop the growth of cancer cells.
A total of 57 enrolled patients with advanced solid tumors, including 19 patients with HR+/HER2- metastatic breast cancer, received BG-68501 as monotherapy or in combination with fulvestrant in escalating dose cohorts (all received prior CDK4/6i).
Of the 37 efficacy-evaluable patients (all with monotherapy), unconfirmed overall response rate (ORR) was 5.4% (2/37; 95% CI: 0.7%–18.2%). Two extensively pretreated patients (5.4%) experienced unconfirmed partial response (PR), 15 patients (40.5%) had stable disease (SD), 15 patients (40.5%) had progressive disease (PD), and 5 patients (13.5%) were not evaluable/not assessed. Of the 2 patients with PR, both were breast cancer patients, and one was ongoing with treatment at the time of data cutoff, while the other had discontinued treatment. Unconfirmed clinical benefit rate (CBR) was 8.1% (3/37; 95% CI: 1.7%-21.9%) and unconfirmed disease control rate (DCR) was 45.9% (17/37; 95% CI: 29.5%-63.1%). BG-68501 demonstrated a linear PK profile consistent with preclinical data and signs of pharmacodynamic responses.
BG-68501 demonstrated a manageable safety and tolerability profile, with no DLTs observed to date during dose escalation. The most common TEAEs were vomiting, nausea, and fatigue, and TEAEs leading to treatment discontinuation occurred in 4 patients (7%) across all dose levels. There were no TEAEs leading to death.
The data support continued development of BG-68501 as a next-line option for tumors with CDK2 dependency. (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06257264&amp;esheet=54263182&amp;newsitemid=20250602546858&amp;lan=en-US&amp;anchor=NCT06257264&amp;index=5&amp;md5=6e6fe01d115e2db279de5928e00f23f3">NCT06257264</a>)

BeOne Medicines Announced New Clinical Data From Its Breast Cancer Pipeline At The American Society Of Clinical Oncology Annual Meeting, Poster Presentations Feature Preliminary Results Of The Dose Escalation Studies Of: BG-C9074 For Advanced Solid Tumors, Including Breast Cancer, And BG-68501 For In HR+/HER2- Breast Cancer Patients With Prior CDK4/6i Exposure

Corpay, Inc.&#x2A;, (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPAY#NYSE">CPAY</a>) a global leader in corporate payments, is pleased to announce that Corpay's Cross-Border business has entered into an agreement with Real Madrid C.F. to become an Official Partner.
Through this partnership, Real Madrid will be able to gain access to and utilise Corpay Cross Border's innovative solutions to help mitigate foreign exchange exposure from their day-to-day business needs.

CPAY

Corpay Teams Up With Real Madrid to Help Manage Currency Risks in Global Operations

<ul>
<li>Definitive agreement to result in one-time $225 million cash payment&nbsp;</li>
<li>Theravance Biopharma retains&nbsp;rights to up to $150 million in milestones from Royalty Pharma on Trelegy Ellipta net sales in 2025 and 2026, requiring minimal to no growth over 2024 actuals to be achieved</li>
<li>$225 million from royalty transaction announced today,&nbsp;in addition to the $1.1 billion upfront received in 2022, and up to $200 million in milestones (of which $50 million was received in 2025), brings total potential lifetime value from Trelegy Ellipta&nbsp;monetization efforts to $1.525 billion</li>
<li>First outcome from Strategic Review Committee's ongoing efforts to maximize shareholder value; Board remains&nbsp;committed to returning excess capital to shareholders</li>
</ul>

Theravance Biopharma Secures $225M In Cash From GSK Deal, Bringing Total Trelegy Monetization Value To $1.525B

During the pre-market trading session on Monday, Shell PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHELL#NYSE">SHELL</a>) and Occidental Petroleum Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) climbed 1.75% and 1.41%, respectively, whereas Exxon Mobil Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) and Chevron Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) climbed 0.88% and 0.85%, each oil prices witnessed more than 3% surge on Monday. This was because the OPEC+ group decided to maintain the output increase for July, mirroring the hikes of the previous two months.
What Happened:&nbsp;Brent crude futures escalated&nbsp;by 2.95%, to&nbsp;$63.22 a barrel. Concurrently,&nbsp;U.S. West Texas Intermediate crude&nbsp;saw an increase of 3.49%, to $62.90. OPEC and its allies, known as OPEC+, have agreed to raise oil production by 411,000 barrels per day in July—marking the third straight month of increases at this volume, reported Reuters.
OPEC and its allies, known as OPEC+, have agreed to raise oil production by 411,000 barrels per day in July—marking the third straight month of increases at this volume. Sources close to OPEC+ talks hinted that the organization could discuss a larger increase. Oil traders had already factored in the 411,000 bpd increase to Brent and WTI futures. 
<path fill-rule="evenodd" clip-rule="evenodd" d="M7 5C7 3.34315 8.34315 2 10 2H19C20.6569 2 22 3.34315 22 5V14C22 15.6569 20.6569 17 19 17H17V19C17 20.6569 15.6569 22 14 22H5C3.34315 22 2 20.6569 2 19V10C2 8.34315 3.34315 7 5 7H7V5ZM9 7H14C15.6569 7 17 8.34315 17 10V15H19C19.5523 15 20 14.5523 20 14V5C20 4.44772 19.5523 4 19 4H10C9.44772 4 9 4.44772 9 5V7ZM5 9C4.44772 9 4 9.44772 4 10V19C4 19.5523 4.44772 20 5 20H14C14.5523 20 15 19.5523 15 19V10C15 9.44772 14.5523 9 14 9H5Z" fill="currentColor"></path>
<path fill-rule="evenodd" clip-rule="evenodd" d="M12.1318 2.50389C12.3321 2.15338 12.7235 1.95768 13.124 2.00775L13.5778 2.06447C16.0449 2.37286 17.636 4.83353 16.9048 7.20993L16.354 8.99999H17.0722C19.7097 8.99999 21.6253 11.5079 20.9313 14.0525L19.5677 19.0525C19.0931 20.7927 17.5124 22 15.7086 22H6C4.34315 22 3 20.6568 3 19V12C3 10.3431 4.34315 8.99999 6 8.99999H8C8.25952 8.99999 8.49914 8.86094 8.6279 8.63561L12.1318 2.50389ZM10 20H15.7086C16.6105 20 17.4008 19.3964 17.6381 18.5262L19.0018 13.5262C19.3488 12.2539 18.391 11 17.0722 11H15C14.6827 11 14.3841 10.8494 14.1956 10.5941C14.0071 10.3388 13.9509 10.0092 14.0442 9.70591L14.9932 6.62175C15.3384 5.49984 14.6484 4.34036 13.5319 4.08468L10.3644 9.62789C10.0522 10.1742 9.56691 10.5859 9 10.8098V19C9 19.5523 9.44772 20 10 20ZM7 11V19C7 19.3506 7.06015 19.6872 7.17071 20H6C5.44772 20 5 19.5523 5 19V12C5 11.4477 5.44772 11 6 11H7Z" fill="currentColor"></path>
<path fill-rule="evenodd" clip-rule="evenodd" d="M11.8727 21.4961C11.6725 21.8466 11.2811 22.0423 10.8805 21.9922L10.4267 21.9355C7.95958 21.6271 6.36855 19.1665 7.09975 16.7901L7.65054 15H6.93226C4.29476 15 2.37923 12.4921 3.0732 9.94753L4.43684 4.94753C4.91145 3.20728 6.49209 2 8.29589 2H18.0045C19.6614 2 21.0045 3.34315 21.0045 5V12C21.0045 13.6569 19.6614 15 18.0045 15H16.0045C15.745 15 15.5054 15.1391 15.3766 15.3644L11.8727 21.4961ZM14.0045 4H8.29589C7.39399 4 6.60367 4.60364 6.36637 5.47376L5.00273 10.4738C4.65574 11.746 5.61351 13 6.93226 13H9.00451C9.32185 13 9.62036 13.1506 9.8089 13.4059C9.99743 13.6612 10.0536 13.9908 9.96028 14.2941L9.01131 17.3782C8.6661 18.5002 9.35608 19.6596 10.4726 19.9153L13.6401 14.3721C13.9523 13.8258 14.4376 13.4141 15.0045 13.1902V5C15.0045 4.44772 14.5568 4 14.0045 4ZM17.0045 13V5C17.0045 4.64937 16.9444 4.31278 16.8338 4H18.0045C18.5568 4 19.0045 4.44772 19.0045 5V12C19.0045 12.5523 18.5568 13 18.0045 13H17.0045Z" fill="currentColor"></path>
<path d="M2.5 5.5C4.3 5.2 5.2 4 5.5 2.5C5.8 4 6.7 5.2 8.5 5.5C6.7 5.8 5.8 7 5.5 8.5C5.2 7 4.3 5.8 2.5 5.5Z" fill="currentColor" stroke="currentColor" stroke-linecap="round" stroke-linejoin="round"></path>
<path d="M5.66282 16.5231L5.18413 19.3952C5.12203 19.7678 5.09098 19.9541 5.14876 20.0888C5.19933 20.2067 5.29328 20.3007 5.41118 20.3512C5.54589 20.409 5.73218 20.378 6.10476 20.3159L8.97693 19.8372C9.72813 19.712 10.1037 19.6494 10.4542 19.521C10.7652 19.407 11.0608 19.2549 11.3343 19.068C11.6425 18.8575 11.9118 18.5882 12.4503 18.0497L20 10.5C21.3807 9.11929 21.3807 6.88071 20 5.5C18.6193 4.11929 16.3807 4.11929 15 5.5L7.45026 13.0497C6.91175 13.5882 6.6425 13.8575 6.43197 14.1657C6.24513 14.4392 6.09299 14.7348 5.97903 15.0458C5.85062 15.3963 5.78802 15.7719 5.66282 16.5231Z" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"></path>
<path d="M14.5 7L18.5 11" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"></path> 
<path d="M3.06957 10.8763C3.62331 6.43564 7.40967 3 12 3C14.2824 3 16.4028 3.85067 18.0118 5.25439V4C18.0118 3.44772 18.4595 3 19.0118 3C19.5641 3 20.0118 3.44772 20.0118 4V8C20.0118 8.55228 19.5641 9 19.0118 9H15C14.4477 9 14 8.55228 14 8C14 7.44772 14.4477 7 15 7H16.9571C15.6757 5.76379 13.9101 5 12 5C8.43108 5 5.48466 7.67174 5.0542 11.1237C4.98586 11.6718 4.48619 12.0607 3.93815 11.9923C3.39011 11.924 3.00123 11.4243 3.06957 10.8763ZM20.0618 12.0077C20.6099 12.076 20.9988 12.5757 20.9304 13.1237C20.3767 17.5644 16.5903 21 12 21C9.72322 21 7.60762 20.1535 5.99999 18.7559V20C5.99999 20.5523 5.55228 21 4.99999 21C4.44771 21 3.99999 20.5523 3.99999 20V16C3.99999 15.4477 4.44771 15 4.99999 15H8.99999C9.55228 15 9.99999 15.4477 9.99999 16C9.99999 16.5523 9.55228 17 8.99999 17H7.04285C8.32433 18.2362 10.0899 19 12 19C15.5689 19 18.5153 16.3283 18.9458 12.8763C19.0141 12.3282 19.5138 11.9393 20.0618 12.0077Z" fill="currentColor"></path>
<path fill-rule="evenodd" clip-rule="evenodd" d="M5.29289 9.29289C5.68342 8.90237 6.31658 8.90237 6.70711 9.29289L12 14.5858L17.2929 9.29289C17.6834 8.90237 18.3166 8.90237 18.7071 9.29289C19.0976 9.68342 19.0976 10.3166 18.7071 10.7071L12.7071 16.7071C12.5196 16.8946 12.2652 17 12 17C11.7348 17 11.4804 16.8946 11.2929 16.7071L5.29289 10.7071C4.90237 10.3166 4.90237 9.68342 5.29289 9.29289Z" fill="currentColor"></path>
Meanwhile, Kazakhstan has notified OPEC of its refusal to cut oil production, according to Russia&#8217;s Interfax news agency. Analysts say this, combined with a decline in market share, has left OPEC+ with limited options.
SEE ALSO: <a href="https://benzinga.com/cannabis/25/06/45714519/ross-ulbricht-the-silk-road-founder-pardoned-by-trump-soon-after-his-inauguration-receives-a-whopping-31" target="_blank" rel="noreferrer noopener">Ross Ulbricht, The Silk Road Founder Pardoned By Trump Soon After His Inauguration, Receives A Whopping $31 Million Worth Of Bitcoin In Donation Wallet</a> 
<path fill-rule="evenodd" clip-rule="evenodd" d="M7 5C7 3.34315 8.34315 2 10 2H19C20.6569 2 22 3.34315 22 5V14C22 15.6569 20.6569 17 19 17H17V19C17 20.6569 15.6569 22 14 22H5C3.34315 22 2 20.6569 2 19V10C2 8.34315 3.34315 7 5 7H7V5ZM9 7H14C15.6569 7 17 8.34315 17 10V15H19C19.5523 15 20 14.5523 20 14V5C20 4.44772 19.5523 4 19 4H10C9.44772 4 9 4.44772 9 5V7ZM5 9C4.44772 9 4 9.44772 4 10V19C4 19.5523 4.44772 20 5 20H14C14.5523 20 15 19.5523 15 19V10C15 9.44772 14.5523 9 14 9H5Z" fill="currentColor"></path>
<path fill-rule="evenodd" clip-rule="evenodd" d="M12.1318 2.50389C12.3321 2.15338 12.7235 1.95768 13.124 2.00775L13.5778 2.06447C16.0449 2.37286 17.636 4.83353 16.9048 7.20993L16.354 8.99999H17.0722C19.7097 8.99999 21.6253 11.5079 20.9313 14.0525L19.5677 19.0525C19.0931 20.7927 17.5124 22 15.7086 22H6C4.34315 22 3 20.6568 3 19V12C3 10.3431 4.34315 8.99999 6 8.99999H8C8.25952 8.99999 8.49914 8.86094 8.6279 8.63561L12.1318 2.50389ZM10 20H15.7086C16.6105 20 17.4008 19.3964 17.6381 18.5262L19.0018 13.5262C19.3488 12.2539 18.391 11 17.0722 11H15C14.6827 11 14.3841 10.8494 14.1956 10.5941C14.0071 10.3388 13.9509 10.0092 14.0442 9.70591L14.9932 6.62175C15.3384 5.49984 14.6484 4.34036 13.5319 4.08468L10.3644 9.62789C10.0522 10.1742 9.56691 10.5859 9 10.8098V19C9 19.5523 9.44772 20 10 20ZM7 11V19C7 19.3506 7.06015 19.6872 7.17071 20H6C5.44772 20 5 19.5523 5 19V12C5 11.4477 5.44772 11 6 11H7Z" fill="currentColor"></path>
<path fill-rule="evenodd" clip-rule="evenodd" d="M11.8727 21.4961C11.6725 21.8466 11.2811 22.0423 10.8805 21.9922L10.4267 21.9355C7.95958 21.6271 6.36855 19.1665 7.09975 16.7901L7.65054 15H6.93226C4.29476 15 2.37923 12.4921 3.0732 9.94753L4.43684 4.94753C4.91145 3.20728 6.49209 2 8.29589 2H18.0045C19.6614 2 21.0045 3.34315 21.0045 5V12C21.0045 13.6569 19.6614 15 18.0045 15H16.0045C15.745 15 15.5054 15.1391 15.3766 15.3644L11.8727 21.4961ZM14.0045 4H8.29589C7.39399 4 6.60367 4.60364 6.36637 5.47376L5.00273 10.4738C4.65574 11.746 5.61351 13 6.93226 13H9.00451C9.32185 13 9.62036 13.1506 9.8089 13.4059C9.99743 13.6612 10.0536 13.9908 9.96028 14.2941L9.01131 17.3782C8.6661 18.5002 9.35608 19.6596 10.4726 19.9153L13.6401 14.3721C13.9523 13.8258 14.4376 13.4141 15.0045 13.1902V5C15.0045 4.44772 14.5568 4 14.0045 4ZM17.0045 13V5C17.0045 4.64937 16.9444 4.31278 16.8338 4H18.0045C18.5568 4 19.0045 4.44772 19.0045 5V12C19.0045 12.5523 18.5568 13 18.0045 13H17.0045Z" fill="currentColor"></path>
<path d="M2.5 5.5C4.3 5.2 5.2 4 5.5 2.5C5.8 4 6.7 5.2 8.5 5.5C6.7 5.8 5.8 7 5.5 8.5C5.2 7 4.3 5.8 2.5 5.5Z" fill="currentColor" stroke="currentColor" stroke-linecap="round" stroke-linejoin="round"></path>
<path d="M5.66282 16.5231L5.18413 19.3952C5.12203 19.7678 5.09098 19.9541 5.14876 20.0888C5.19933 20.2067 5.29328 20.3007 5.41118 20.3512C5.54589 20.409 5.73218 20.378 6.10476 20.3159L8.97693 19.8372C9.72813 19.712 10.1037 19.6494 10.4542 19.521C10.7652 19.407 11.0608 19.2549 11.3343 19.068C11.6425 18.8575 11.9118 18.5882 12.4503 18.0497L20 10.5C21.3807 9.11929 21.3807 6.88071 20 5.5C18.6193 4.11929 16.3807 4.11929 15 5.5L7.45026 13.0497C6.91175 13.5882 6.6425 13.8575 6.43197 14.1657C6.24513 14.4392 6.09299 14.7348 5.97903 15.0458C5.85062 15.3963 5.78802 15.7719 5.66282 16.5231Z" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"></path>
<path d="M14.5 7L18.5 11" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"></path> 
<path d="M3.06957 10.8763C3.62331 6.43564 7.40967 3 12 3C14.2824 3 16.4028 3.85067 18.0118 5.25439V4C18.0118 3.44772 18.4595 3 19.0118 3C19.5641 3 20.0118 3.44772 20.0118 4V8C20.0118 8.55228 19.5641 9 19.0118 9H15C14.4477 9 14 8.55228 14 8C14 7.44772 14.4477 7 15 7H16.9571C15.6757 5.76379 13.9101 5 12 5C8.43108 5 5.48466 7.67174 5.0542 11.1237C4.98586 11.6718 4.48619 12.0607 3.93815 11.9923C3.39011 11.924 3.00123 11.4243 3.06957 10.8763ZM20.0618 12.0077C20.6099 12.076 20.9988 12.5757 20.9304 13.1237C20.3767 17.5644 16.5903 21 12 21C9.72322 21 7.60762 20.1535 5.99999 18.7559V20C5.99999 20.5523 5.55228 21 4.99999 21C4.44771 21 3.99999 20.5523 3.99999 20V16C3.99999 15.4477 4.44771 15 4.99999 15H8.99999C9.55228 15 9.99999 15.4477 9.99999 16C9.99999 16.5523 9.55228 17 8.99999 17H7.04285C8.32433 18.2362 10.0899 19 12 19C15.5689 19 18.5153 16.3283 18.9458 12.8763C19.0141 12.3282 19.5138 11.9393 20.0618 12.0077Z" fill="currentColor"></path>
<path fill-rule="evenodd" clip-rule="evenodd" d="M5.29289 9.29289C5.68342 8.90237 6.31658 8.90237 6.70711 9.29289L12 14.5858L17.2929 9.29289C17.6834 8.90237 18.3166 8.90237 18.7071 9.29289C19.0976 9.68342 19.0976 10.3166 18.7071 10.7071L12.7071 16.7071C12.5196 16.8946 12.2652 17 12 17C11.7348 17 11.4804 16.8946 11.2929 16.7071L5.29289 10.7071C4.90237 10.3166 4.90237 9.68342 5.29289 9.29289Z" fill="currentColor"></path>
Why It Matters: This decision by OPEC+ comes at a time when the global oil industry is witnessing <a href="https://www.benzinga.com/news/global/25/05/45655155/exxon-stock-vs-chevron-the-11-billion-barrel-oil-war-that-could-shake-up-energy-etfs">significant changes</a>. For instance, reports highlighted an ongoing battle between Chevron Corp and Exxon Mobil Corp for a share of one of the world&#8217;s most coveted oil finds in Guyana. This fight, centered around Hess Corp&#8217;s 30% interest in a massive Guyanese oil project, could potentially impact some of the largest energy ETFs available.
Despite the ongoing oil war, the decision to keep output levels steady has led to a surge in oil prices. This could have implications for the wider energy market.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/politics/25/06/45715447/xi-jinpings-china-dismisses-trumps-groundless-accusations-on-geneva-trade-deal-breach-vows-strong-r" target="_blank" rel="noreferrer noopener">Xi Jinping&#8217;s China Dismisses Trump&#8217;s &#8216;Groundless&#8217; Accusations On Geneva Trade Deal Breach, Vows Strong Retaliation</a> </li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

SHELL

Shell, Occidental Petroleum And Exxon Mobil Rise In Monday Premarket: What's Going On?

RBC Capital analyst Nik Modi upgrades Church &amp; Dwight Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHD#NYSE">CHD</a>) from Sector Perform to Outperform and raises the price target from $100 to $114.

Upgrades

RBC Capital Upgrades Church & Dwight Co to Outperform, Raises Price Target to $114

Press Releases

Bolt Threads Announces Closing of Business Combination and Will Begin Trading on Nasdaq Under New Symbol "BSLK"

Bolt Projects Holdings Announces More Brands Choosing b-silk™ to Differentiate Their Product Offerings

Bolt Projects Reports Q3 2024 Financial Results

Bolt Partners with Goddess Maintenance Co. for Groundbreaking Beauty Launch

Bolt Projects Reports Q4 2024 Financial Results

Bolt Projects Holdings Reports Q1 2025 Financial Results

The CHIPS Act and Peraso Inc. (NASDAQ: PRSO): Advancing Semiconductor Innovation and National Security – More Stocks Inside

BLRX

BMGL

GAMC

PRSO

SNYR

TIRX

VIVK

AdvanSix

Braskem

Cabot

Core Molding Technologies Inc Common Stock

Core Molding Technologies

CN Energy Group Inc. - Class A Ordinary Shares

CN Energy Group

Gulf Resources

Hawkins

Koppers Holdings

Kronos Worldwide

Loop Industries

Mativ Holdings

Orion

Olin

Origin Materials, Inc. - Class A Common Stock

Origin Materials

PureCycle Technologies, Inc. - Common stock

PureCycle Technologies

Tronox Holdings

Trinseo

Westlake

Westlake Chemical Partners LP Common Units representing limited partner interests

Comments

Bolt Projects Holdings

Vendite allo scoperto

Bolt Projects Holdings (NASDAQ:BSLK) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO